

DAFTAR PUSTAKA

1. Shiels MS, Katki HA, Freedman ND, et al. Cigarette smoking and variations in systemic immune and inflammation markers. *J Natl Cancer Inst* 2014;106(11):1–8.
2. World Health Organization. Country Profile : Indonesia. *Glob Tuberc Control* 2012;(December):2006–2009.
3. Kemenkes Republik Indonesia. TEMBAKAU di Indonesia TEMBAKAU di Indonesia [Internet]. 2014. Available from: <http://www.depkes.go.id/download.php?file=download/pusdatin/infodatin/infodatin-hari-tanpa-tembakau-sedunia.pdf>
4. Riskesdas K. Hasil Utama Riset Kesehata Dasar (RISKESDAS) [Internet]. 2018. Available from: <http://arxiv.org/abs/1011.1669%0A> <http://dx.doi.org/10.1088/1751-8113/44/8/085201%0A> <http://stacks.iop.org/1751-8121/44/i=8/a=085201?key=crossref.abc74c979a75846b3de48a5587bf708f>
5. Wu Q, Jiang D, Minor M, Chu HW. Electronic cigarette liquid increases inflammation and virus infection in primary human airway epithelial cells. *PLoS One* 2014;9(9).
6. Bareham SAG and DW. E-Cigarettes: Use, Effects on Smoking, Risks, and Policy Implications Stanton. *Annu Rev ofPublic Heal E-Cigarettes* 2018;39:28.1-28.21.
7. Qasim H, Karim ZA, Rivera JO, Khasawneh FT, Alshbool FZ. Impact of electronic cigarettes on the cardiovascular system. *J Am Heart Assoc* 2017;6(9).
8. Chen, I-Ling; Todd, Ian; Fairclough LC. Immunological and pathological effects of electronic cigarettes. *Basic Clin Pharmacol Toxicol* 2019;1–16.
9. World Bank Group. E-ECIGARETTES: USE AND TAXATION WBG Global Tobacco Control Program Team WORKING NOTE [Internet]. 2019. Available from: <http://documents.worldbank.org/curated/en/356561555100066200/pdf/E-Cigarettes-Use-and-Taxation.pdf>
10. IAKMI T. Atlas Tembakau Indonesia Tahun 2020. 2020;33.
11. Drummond MB, Upton D. Electronic cigarettes: Potential harms and benefits. *Ann Am Thorac Soc* 2014;11(2):236–242.
12. Pisinger C. A systematic review of health effects of electronic cigarettes. 2015.
13. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EFM. Systemic effects of smoking. *Chest* [Internet] 2007;131(5):1557–1566. Available from: <http://dx.doi.org/10.1378/chest.06-2179>
14. Foronjy, Robert; D'Armiento J. The Effect of Cigarette Smoke-derived Oxidants on the Inflammatory Response of the Lung. *Clin Appl Immunol Rev* 2006;6(1):53–72.
15. Taito S, Hamada H, Sekikawa K, Kamikawa N, Takahashi M. Oxidative stress in cigarette smokers and patients with chronic obstructive pulmonary disease. *Oxid Antioxid Med Sci* 2017;6(2):19.

16. Chandra M, Panchatcharam M, Sumitra M. Biomarkers Role of Isoprostanes in Oxidative Stess. *Free Radicals Dis* 2016;131–148.
17. Morrow JD, Roberts LJ. The isoprostanes: Their role as an index of oxidant stress status in human pulmonary disease. *Am J Respir Crit Care Med* 2002;166(12 II):25–30.
18. Carmella SG, Heskin AK, Tang MK, et al. Longitudinal stability in cigarette smokers of urinary eicosanoid biomarkers of oxidative damage and inflammation. *PLoS One* 2019;14(4):1–15.
19. Kaur G, Pinkston R, McLemore B, Dorsey WC, Batra S. Immunological and toxicological risk assessment of e-cigarettes. *Eur Respir Rev* [Internet] 2018;27(147). Available from: <http://dx.doi.org/10.1183/16000617.0119-2017>
20. Tamimi A, Serdarevic D, Hanania NA. The effects of cigarette smoke on airway inflammation in asthma and COPD: Therapeutic implications. *Respir Med* [Internet] 2012;106(3):319–328. Available from: <http://dx.doi.org/10.1016/j.rmed.2011.11.003>
21. Shields PG, Berman M, Brasky TM, et al. A review of pulmonary toxicity of electronic cigarettes in the context of smoking: A focus on inflammation. *Cancer Epidemiol Biomarkers Prev* 2017;26(8):1175–1191.
22. Grana R, Benowitz N, Glantz SA. E-cigarettes: A scientific review. *Circulation* 2014;129(19):1972–1986.
23. Son Y, Mishin V, Laskin JD, et al. Hydroxyl Radicals in E-Cigarette Vapor and E-Vapor Oxidative Potentials under Different Vaping Patterns. *Chem Res Toxicol* 2019;32(6):1087–1095.
24. Kaur, Gurjot; Muthumalage, Thivanka; Rahman I. Mechanisms of toxicity and biomarkers of flavoring and flavor enhancing chemicals in emerging tobacco and non-tobacco products Gurjot. *Toxicol Lett* 20118;188:143–155.
25. Cervellati F, Muresan X, Sticozzi C, et al. Comparative effects between electronic and cigarette smoke in human keratinocytes and epithelial lung cells. *Toxicol Vitr* 2014;28(5):999–1005.
26. Higham A, Rattray NJW, Dewhurst JA, et al. Electronic cigarette exposure triggers neutrophil inflammatory responses. *Respir Res* [Internet] 2016;17(1):1–11. Available from: <http://dx.doi.org/10.1186/s12931-016-0368-x>
27. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. *J Autoimmun* [Internet] 2010;34(3):J258–J265. Available from: <http://dx.doi.org/10.1016/j.jaut.2009.12.003>
28. Ryan H, Trosclair A, Gfroerer J. Adult current smoking: Differences in definitions and prevalence estimates - NHIS and NSDUH, 2008. *J Environ Public Health* 2012;2012:1–11.
29. Indonesia KMPDPR. Tentang Pedoman Cara Uji Kandungan Kadar Nikotin dan Tar Rokok.
30. Indonesia KMKR. Penetapan Tarif Cukai dan Harga Dasar Hasil Tembakau.
31. Dian A. Jenis-Jenis Rokok yang Beredar di Indonesia. 2020; Available from: <https://www.tobakonis.com/rokok/jenis-jenis-rokok/>
32. Susanna, Dewi; Hartono, Budi; Fauzan H. Penentuan Kadar Nikotin Dalam Asap/Level of Nicotine Content in Cigarettes. *J Ekol Kesehatan* 2003;2(3):272–274.

33. Strzelak, Agnieszka; Ratajczak Aleksandra; Adamiec, Aleksander; Feleszko W. Tobacco Smoke Induces and Alters Immune Responses in the Lung Triggering Inflammation, Allergy, Asthma and Other Lung Diseases: A Mechanistic Review Agnieszka. *Int J Environ Res Public Heal* 2018;15(1033):1–35.
34. Bhalla DK, Hirata F, Rishi AK, Gairola CG. Cigarette smoke, inflammation, and lung injury: A mechanistic perspective. *J Toxicol Environ Heal - Part B Crit Rev* 2009;12(1):45–64.
35. Domgala-Kulawik J. Effects of Cigarette Smoke on the Lung. *J Physiol Pharmacol* 2008;59(suppl 6):19–34.
36. Fowles J, Bates M. The Chemical Constituents in Cigarettes and Cigarette Smoke A Report to the New Zealand Ministry of Health. 2000.
37. Zevin S, Saunders S, Gourlay SG, Jacob P, Benowitz NL. Cardiovascular effects of carbon monoxide and cigarette smoking. *J Am Coll Cardiol* [Internet] 2001;38(6):1633–1638. Available from: [http://dx.doi.org/10.1016/S0735-1097\(01\)01616-3](http://dx.doi.org/10.1016/S0735-1097(01)01616-3)
38. Harris JE. Cigarette smoke somponents and disease: Cigarette smoke is More than a triad of tar, nicotine and carbon monoxide. *Smok Tob Control Monogr No 7* 1991;59–75.
39. Barnes PJ. The cytokine network in chronic obstructive pulmonary disease. *Am J Respir Cell Mol Biol* 2009;41(6):631–638.
40. Lacy P, Stow JL. Cytokine release from innate immune cells: Association with diverse membrane trafficking pathways. *Blood* 2011;118(1):9–18.
41. Valavanidis A, Vlachogianni T, Fiotakis K. Tobacco smoke: Involvement of reactive oxygen species and stable free radicals in mechanisms of oxidative damage, carcinogenesis and synergistic effects with other respirable particles. *Int J Environ Res Public Health* 2009;6(2):445–462.
42. Aula FA, Qadir FA. Effects of Cigarette Smoking on Some Immunological and Hematological Parameters in Male Smokers in Erbil City. *Jordan J Biol Sci* 2013;6(2):159–166.
43. Montuschi P, Barnes PJ, Roberts LJ. Isoprostanes: markers and mediators of oxidative stress. *FASEB J* 2004;18(15):1791–1800.
44. Peck MJ, Sanders EB, Scherer G, Lüdicke F, Weitkunat R. Review of biomarkers to assess the effects of switching from cigarettes to modified risk tobacco products. *Biomarkers* [Internet] 2018;23(3):213–244. Available from: <https://doi.org/10.1080/1354750X.2017.1419284>
45. Milne GL, Yin H, Hardy KD, Davies SS, Roberts LJ. Isoprostane generation and function. *Chem Rev* 2011;111(10):5973–5996.
46. Callewaert, Denis; Sloan C. Enzyme Immunoassay of Isoprostanes [Internet]. In: Uppu, Rao M ; Murthy, Subramanyam N ; Pryor, William A ; Parinandi NL, editor. Free Radicals and Antioxidant Protocols, Methods in Molecular Biology. New Orleans: Humana Press; 2010. p. 435–449. Available from: <http://link.springer.com/10.1007/978-1-60327-029-8>
47. Helmersson H, Basu S. F2-isoprostane excretion rate and diurnal variation in human urine. *Prostaglandins Leukot Essent Fat Acids* 1999;61(3):203–205.

48. Viau C, Lafontaine M, Payan JP. Creatinine normalization in biological monitoring revisited: The case of 1-hydroxypyrene. *Int Arch Occup Environ Health* 2004;77(3):177–185.
49. Plas A van der, Pouly S, La Bourdonnaye G de, Baker G, Lüdicke F. Influence of smoking on levels of urinary 8-iso Prostaglandin F2 α . *Toxicol Reports* 2019;6(October 2018):18–25.
50. Rincon M, Irvin CG. Role of IL-6 in asthma and other inflammatory pulmonary diseases. *Int J Biol Sci* 2012;8(9):1281–1290.
51. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. *Biochim Biophys Acta - Mol Cell Res* 2011;1813(5):878–888.
52. Zuo L, He F, Sergakis GG, et al. Interrelated role of cigarette smoking, oxidative stress, and immune response in COPD and corresponding treatments. *Am J Physiol - Lung Cell Mol Physiol* 2014;307(3).
53. Walter RE, Wilk JB, Larson MG, et al. Systemic inflammation and COPD: The Framingham heart study. *Chest* [Internet] 2008;133(1):19–25. Available from: <http://dx.doi.org/10.1378/chest.07-0058>
54. Maggio M, Guralnik JM, Longo DL, Ferrucci L. Interleukin-6 in aging and chronic disease: A magnificent pathway. *Journals Gerontol - Ser A Biol Sci Med Sci* 2006;61(6):575–584.
55. Glund S, Deshmukh A, Long YC, et al. Interleukin-6 Directly Increases Glucose Metabolism in Resting Human Skeletal Muscle. *Diabetes* 2007;56(June):1630–1637.
56. Kawaguchi Y. Contribution of interleukin-6 to the pathogenesis of systemic sclerosis. *J Scleroderma Relat Disord* 2017;2(Suppl 2):S6–S12.
57. Ganeshan K, Johnston LK, Bryce PJ. TGF- β 1 Limits the Onset of Innate Lung Inflammation by Promoting Mast Cell-Derived IL-6. *J Immunol* 2013;190(11):5731–5738.
58. Liang R, Zhang W, Song YM. Levels of leptin and IL-6 in lungs and blood are associated with the severity of chronic obstructive pulmonary disease in patients and rat models. *Mol Med Rep* 2013;7(5):1470–1476.
59. Barbar MPF, Carpagnan GE, Spanevellol A, et al. Inflammation, Oxidative Stress and Systemic Effects in Mild Chronic obstructive pulmonary diseases (COPD). *Int J Immunopathol Pharmacol* 2007;20(4):753–763.
60. Benowitz NL, Hukkanen J, Iii PJ. Nicotine Chemistry metabolism and kinetics. *Handb Exp Pharmacol* 2009;192:29–60.
61. Kusuma DA, Yuwono SS, Wulan SN. Studi Kadar Nikotin dan Tar Sembilan Merk Rokok Kretek Filter yang Beredar di Wilayah Kabupaten Nganjuk. *Jur Teknol Pertan* 2012;5(3):151–155.
62. Amanati, L; Murni M. Pengamatan kandungan tar dan nikotin di pabrik dan pasar. *Ber Litbang Ind* 2010;XLV(3):52–57.
63. England LJ, Bunnell RE, Pechacek TF, Tong VT, McAfee TA. Nicotine and the Developing Human: A Neglected Element in the Electronic Cigarette Debate. *Am J Prev Med* [Internet] 2015;49(2):286–293. Available from: <http://dx.doi.org/10.1016/j.amepre.2015.01.015>
64. Romberg AR, Miller Lo EJ, Cuccia AF, et al. Patterns of nicotine concentrations in electronic cigarettes sold in the United States, 2013-2018. *Drug Alcohol Depend* 2019;203(February):1–7.

65. Yingst JM, Foulds J, Veldheer S, et al. Nicotine absorption during electronic cigarette use among regular users. *PLoS One* 2019;14(7):1–15.
66. Marsot, A; Simon N. Nicotine and Cotinine Levels With Electronic Cigarette: A Review. *Int J Toxicol* 2016, 2016;35(2):179–185.
67. Sopori M. Effects of cigarette smoke on the immune system. *Nat Rev Immunol* 2002;2(5):372–377.
68. Susanto, Agus Dwi; Fitriani, Feni; Iksan, Muktar; Antariksa, Budhi; Hudoyo, Ahmad; Mansyur, Amalia K; Rusli, Adria; Hasan, Azril; Jusuf, Anwar; Yunus F. Berhenti Merokok. Perhimpunan Dokter Paru Indonesia; 2011.
69. Mehta H, Nazzal K, Sadikot RT. Cigarette smoking and innate immunity. *Inflamm Res* 2008;57(11):497–503.
70. Piao WH, Campagnolo D, Dayao C, Lukas RJ, Wu J, Shi FD. Nicotine and inflammatory neurological disorders. *Acta Pharmacol Sin* 2009;30(6):715–722.
71. Nouri-Shirazi M, Guinet E. Evidence for the immunosuppressive role of nicotine on human dendritic cell functions. *Immunology* 2003;109(3):365–373.
72. Elsa, Syahrawani Elsa; Nadjib M. Deter minan rokok e le ktr ik di Indonesia : data SUSENAS (Survei Sosial Ekonomi Nasional) tahun 2017. 2019;35(2):41–48.
73. BPS. Persentase Merokok Penduduk Pada Umur \geq 15 Tahun Menurut Kelompok Umur 2015-2018. 2020;3857046.
74. Tania POA, Simamora D, Parmasari WD, Rahmawati F. Kadar Interleukin 6 (IL-6) sebagai indikator progresivitas penyakit reumatoid arthritis (RA). *J Ilm Kedokt* 2014;3(1):40–47.
75. Singh KP, Lawyer G, Muthumalage T, et al. Systemic biomarkers in electronic cigarette users: implications for noninvasive assessment of vaping-associated pulmonary injuries. *ERJ Open Res* [Internet] 2019;5(4):00182–02019. Available from: <http://dx.doi.org/10.1183/23120541.00182-2019>
76. Gellatly S, Pavelka N, Crue T, et al. Nicotine-free e-cigarette vapor exposure stimulates IL6 and mucin production in human primary small airway epithelial cells. *J Inflamm Res* 2020;13:175–185.
77. Fernandez-Real JM, Vayreda M, Richart C, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. *J Clin Endocrinol Metab* 2001;86(3):1154–1159.
78. Jamil A, Rashid A, Naveed AK, Asim M. Effect of smoking on interleukin-6 and correlation between IL-6 and serum amyloid a-low density lipoprotein in smokers. *J Postgrad Med Inst* 2017;31(4):336–338.
79. Sakano N, Takahashi N, Wang DH, et al. Plasma 3-nitrotyrosine, urinary 8-isoprostane and 8-OHdG among healthy Japanese people. *Free Radic Res* 2009;43(2):183–192.
80. Graille M, Wild P, Sauvain JJ, Hemmendinger M, Guseva Canu I, Hopf NB. Urinary 8-isoprostane as a biomarker for oxidative stress. A systematic review and meta-analysis. *Toxicol Lett* [Internet] 2020;328(April):19–27. Available from: <https://doi.org/10.1016/j.toxlet.2020.04.006>

81. Ma E, Ingram KH, Milne GL, Timothy Garvey W. F2-isoprostanes reflect oxidative stress correlated with lean mass and bone density but not insulin resistance. *J Endocr Soc* 2017;1(5):436–448.
82. Obata T, Tomaru K, Nagakura T, Izumi Y, Kawamoto T. Smoking and oxidant stress: Assay of isoprostane in human urine by gas chromatography-mass spectrometry. *J Chromatogr B Biomed Sci Appl* 2000;746(1):11–15.
83. Czekala L, Simms L, Stevenson M, Tschierske N, Maione AG, Walele T. Toxicological comparison of cigarette smoke and e-cigarette aerosol using a 3D in vitro human respiratory model. *Regul Toxicol Pharmacol* [Internet] 2019;103(September 2018):314–324. Available from: <https://doi.org/10.1016/j.yrtph.2019.01.036>
84. Czerska M, Zieliński M, Gromadzińska J. Isoprostanes – A novel major group of oxidative stress markers. *Int J Occup Med Environ Health* 2016;29(2):179–190.
85. Bougoulia M, Triantos A, Koliakos G. Plasma interleukin-6 levels, glutathione peroxidase and isoprostane in obese women before and after weight loss. Association with cardiovascular risk factors. *Hormones (Athens)* 2006;5(3):192–199.
86. Gomaa HAM, Shafie MF El, Mohamed KY. Cigarette smoking provoked proinflammatory cytokines and oxidative stress in healthy smokers. *Int J Pharm Clin Res* 2016;8(6):578–582.
87. Aldaham S, Foote JA, Chow HHS, Hakim IA. Smoking Status Effect on Inflammatory Markers in a Randomized Trial of Current and Former Heavy Smokers. *Int J Inflamm* 2015;2015.